Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cervel Neurotech developed a proprietary multi-coil rTMS system for non-invasive deep brain neuromodulation. The technology was based on intellectual property from Stanford University. Their system aimed to improve the precision and efficacy of TMS by targeting deeper or more specific brain regions than conventional single-coil systems. The company’s assets were acquired by Rio Grande Neurosciences, which continues clinical research in multiple neuropsychiatric indications including MDD, chronic pain, PTSD, addiction, OCD, bipolar disorder, mTBI and others.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cervel Neurotech.